🚀 VC round data is live in beta, check it out!
Palvella Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Palvella Therapeutics and similar public comparables like Eczacıbaşı İlaç, Syndax, Zymeworks, Hanall Biopharma and more.
Palvella Therapeutics Overview
About Palvella Therapeutics
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company’s lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company’s patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
Founded
2015
HQ
Employees
14
Website
Sectors
Financials (LTM)
EV
$2B
Palvella Therapeutics Financials
Palvella Therapeutics reported last 12-month revenue of $6K and negative EBITDA of ($41M).
In the same LTM period, Palvella Therapeutics generated $6K in gross profit, ($41M) in EBITDA losses, and had net loss of ($42M).
Revenue (LTM)
Palvella Therapeutics P&L
In the most recent fiscal year, Palvella Therapeutics reported revenue of — and EBITDA of ($13M).
Palvella Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $6K | XXX | — | XXX | XXX | XXX |
| Gross Profit | $6K | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($41M) | XXX | ($13M) | XXX | XXX | XXX |
| EBITDA Margin | (706586%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (717032%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($42M) | XXX | ($17M) | XXX | XXX | XXX |
| Net Margin | (734390%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Palvella Therapeutics Stock Performance
Palvella Therapeutics has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Palvella Therapeutics' stock price is $136.70.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $-1.25 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPalvella Therapeutics Valuation Multiples
Palvella Therapeutics trades at 320323.1x EV/Revenue multiple, and (45.3x) EV/EBITDA.
EV / Revenue (LTM)
Palvella Therapeutics Financial Valuation Multiples
As of March 21, 2026, Palvella Therapeutics has market cap of $2B and EV of $2B.
Equity research analysts estimate Palvella Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Palvella Therapeutics has a P/E ratio of (45.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 320323.1x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (45.3x) | XXX | (140.9x) | XXX | XXX | XXX |
| EV/EBIT | (44.7x) | XXX | (131.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 320323.1x | XXX | — | XXX | XXX | XXX |
| P/E | (45.1x) | XXX | (109.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (170.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Palvella Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Palvella Therapeutics Margins & Growth Rates
Palvella Therapeutics' revenue in the last 12 month grew by 93572%.
Palvella Therapeutics' revenue per employee in the last FY averaged $0.0M.
Palvella Therapeutics' rule of 40 is (613013%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Palvella Therapeutics' rule of X is (472655%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Palvella Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 93572% | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (706586%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | 190% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (613013%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (472655%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 287125% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 431863% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Palvella Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Eczacıbaşı İlaç | XXX | XXX | XXX | XXX | XXX | XXX |
| Syndax | XXX | XXX | XXX | XXX | XXX | XXX |
| Zymeworks | XXX | XXX | XXX | XXX | XXX | XXX |
| Hanall Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Natco Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Palvella Therapeutics M&A Activity
Palvella Therapeutics acquired XXX companies to date.
Last acquisition by Palvella Therapeutics was on XXXXXXXX, XXXXX. Palvella Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Palvella Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPalvella Therapeutics Investment Activity
Palvella Therapeutics invested in XXX companies to date.
Palvella Therapeutics made its latest investment on XXXXXXXX, XXXXX. Palvella Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Palvella Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Palvella Therapeutics
| When was Palvella Therapeutics founded? | Palvella Therapeutics was founded in 2015. |
| Where is Palvella Therapeutics headquartered? | Palvella Therapeutics is headquartered in United States. |
| How many employees does Palvella Therapeutics have? | As of today, Palvella Therapeutics has over 14 employees. |
| Who is the CEO of Palvella Therapeutics? | Palvella Therapeutics' CEO is Wesley H. Kaupinen. |
| Is Palvella Therapeutics publicly listed? | Yes, Palvella Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Palvella Therapeutics? | Palvella Therapeutics trades under PVLA ticker. |
| When did Palvella Therapeutics go public? | Palvella Therapeutics went public in 2024. |
| Who are competitors of Palvella Therapeutics? | Palvella Therapeutics main competitors are Eczacıbaşı İlaç, Syndax, Zymeworks, Hanall Biopharma. |
| What is the current market cap of Palvella Therapeutics? | Palvella Therapeutics' current market cap is $2B. |
| What is the current revenue of Palvella Therapeutics? | Palvella Therapeutics' last 12 months revenue is $6K. |
| What is the current revenue growth of Palvella Therapeutics? | Palvella Therapeutics revenue growth (NTM/LTM) is 93572%. |
| What is the current EV/Revenue multiple of Palvella Therapeutics? | Current revenue multiple of Palvella Therapeutics is 320323.1x. |
| Is Palvella Therapeutics profitable? | No, Palvella Therapeutics is not profitable. |
| What is the current EBITDA of Palvella Therapeutics? | Palvella Therapeutics has negative EBITDA and is not profitable. |
| What is Palvella Therapeutics' EBITDA margin? | Palvella Therapeutics' last 12 months EBITDA margin is (706586%). |
| What is the current EV/EBITDA multiple of Palvella Therapeutics? | Current EBITDA multiple of Palvella Therapeutics is (45.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.